Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035971 · ClinicalTrials.gov registry record · Phase 4
EVA: Evista Alendronate Comparison
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00035971 is a Phase 4 study that has completed, run by Eli Lilly and Company.
The verdict
NCT00035971, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
Interventions
- DRUG raloxifene HCI and alendronate Na
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035971
The ClinicalTrials.gov registry entry for NCT00035971 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which raloxifene HCI and alendronate Na is the first listed.
NCT00035971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035971 about?
NCT00035971 is a clinical study titled "EVA: Evista Alendronate Comparison". The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
What is the current status of trial NCT00035971?
This trial is currently completed. It is a Phase 4 study.
What interventions are being tested in trial NCT00035971?
The interventions under investigation include: raloxifene HCI and alendronate Na (DRUG).
Who is sponsoring clinical trial NCT00035971?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.